1. In Silico Fragment-Based Design Identifies Subfamily B1 Metallo-β-lactamase Inhibitors.
- Author
-
Cain R, Brem J, Zollman D, McDonough MA, Johnson RM, Spencer J, Makena A, Abboud MI, Cahill S, Lee SY, McHugh PJ, Schofield CJ, and Fishwick CWG
- Subjects
- Drug Evaluation, Preclinical, Models, Molecular, Protein Conformation, Structure-Activity Relationship, beta-Lactamases chemistry, Anti-Bacterial Agents chemistry, Anti-Bacterial Agents pharmacology, Computer Simulation, Drug Design, beta-Lactamase Inhibitors chemistry, beta-Lactamase Inhibitors pharmacology, beta-Lactamases metabolism
- Abstract
Zinc ion-dependent β-lactamases (MBLs) catalyze the hydrolysis of almost all β-lactam antibiotics and resist the action of clinically available β-lactamase inhibitors. We report how application of in silico fragment-based molecular design employing thiol-mediated metal anchorage leads to potent MBL inhibitors. The new inhibitors manifest potent inhibition of clinically important B1 subfamily MBLs, including the widespread NDM-1, IMP-1, and VIM-2 enzymes; with lower potency, some of them also inhibit clinically relevant Class A and D serine-β-lactamases. The inhibitors show selectivity for bacterial MBL enzymes compared to that for human MBL fold nucleases. Cocrystallization of one inhibitor, which shows potentiation of Meropenem activity against MBL-expressing Enterobacteriaceae, with VIM-2 reveals an unexpected binding mode, involving interactions with residues from conserved active site bordering loops.
- Published
- 2018
- Full Text
- View/download PDF